Last reviewed · How we verify

Anlotinib combined with paclitaxel and carboplatin, phase I

Chinese Academy of Medical Sciences · Phase 1 active Small molecule Quality 0/100

Anlotinib combined with paclitaxel and carboplatin, phase I is a Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently in Phase 1 development. Also known as: ATC I.

At a glance

Generic nameAnlotinib combined with paclitaxel and carboplatin, phase I
Also known asATC I
SponsorChinese Academy of Medical Sciences
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anlotinib combined with paclitaxel and carboplatin, phase I

What is Anlotinib combined with paclitaxel and carboplatin, phase I?

Anlotinib combined with paclitaxel and carboplatin, phase I is a Small molecule drug developed by Chinese Academy of Medical Sciences.

Who makes Anlotinib combined with paclitaxel and carboplatin, phase I?

Anlotinib combined with paclitaxel and carboplatin, phase I is developed by Chinese Academy of Medical Sciences (see full Chinese Academy of Medical Sciences pipeline at /company/chinese-academy-of-medical-sciences).

Is Anlotinib combined with paclitaxel and carboplatin, phase I also known as anything else?

Anlotinib combined with paclitaxel and carboplatin, phase I is also known as ATC I.

What development phase is Anlotinib combined with paclitaxel and carboplatin, phase I in?

Anlotinib combined with paclitaxel and carboplatin, phase I is in Phase 1.

Related